Crispr Therapeutics (NASDAQ:CRSP) had its price objective upped by Piper Jaffray Companies from $100.00 to $107.00 in a report issued on Tuesday, November 19th, The Fly reports. They currently have a buy rating on the stock.
CRSP has been the topic of a number of other reports. BidaskClub raised shares of Crispr Therapeutics from a hold rating to a buy rating in a report on Friday, November 15th. Barclays upped their price objective on Crispr Therapeutics from $59.00 to $62.00 and gave the stock an overweight rating in a report on Tuesday, July 30th. Zacks Investment Research lowered Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. Needham & Company LLC restated a buy rating and issued a $62.00 target price on shares of Crispr Therapeutics in a research report on Wednesday, July 31st. Finally, Oppenheimer upgraded shares of Crispr Therapeutics from a market perform rating to an outperform rating and set a $65.00 price target on the stock in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $69.54.
NASDAQ CRSP traded down $0.13 during trading hours on Tuesday, hitting $71.97. The company’s stock had a trading volume of 607,081 shares, compared to its average volume of 701,470. The company’s 50-day simple moving average is $53.47 and its two-hundred day simple moving average is $47.06. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The company has a market capitalization of $3.95 billion, a PE ratio of -20.92 and a beta of 3.30. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Research analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last three months. Corporate insiders own 21.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB acquired a new stake in Crispr Therapeutics in the 2nd quarter valued at approximately $207,000. Commonwealth Equity Services LLC grew its holdings in Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after acquiring an additional 986 shares during the period. Buckley Wealth Management LLC purchased a new position in Crispr Therapeutics in the second quarter worth $236,000. Carnegie Capital Asset Management LLC purchased a new position in Crispr Therapeutics in the second quarter worth $1,064,000. Finally, Moody Aldrich Partners LLC acquired a new stake in Crispr Therapeutics in the second quarter valued at $1,838,000. Institutional investors and hedge funds own 49.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Trading Strategy
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.